{'fraction_non_alphanumeric': 0.025, 'fraction_numerical': 0.010294117647058823, 'mean_word_length': 5.247706422018348, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
IVIVE of Bexarotene Metabolism in The Presence of Chronic Kidney Disease and Acute Kidney Injury in Rat Using PBPK Modeling and Extrapolation to Human.

Renal impairment was associated with increased bexarotene fraction unbound in plasma, decreased in vitro intrinsic clearance, and in vivo total plasma clearance in rats. The human physiologically-based pharmacokinetic model predicted an increased bexarotene exposure 1.9-2.1 fold in chronic kidney disease (CKD) stages 3, 4, and 5 as compared to cancer patients, which may require dose reduction and drug monitoring, especially in cancer patients suffering from CKD. This article is protected by copyright. All rights reserved.